ArticleFrontiers in pharmacology2020

Low-Dose of Intrapulmonary Pirfenidone Improves Human Transforming Growth Factorβ1-Driven Lung Fibrosis.

Tomohito Okano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.